Homonymous HemianopiaNCT04827147
Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia
A study testing Multi-Periscopic Prism (MPP) glasses and Fresnel Peripheral Prism (FPP) glasses in people with Homonymous Hemianopia, run by Massachusetts Eye and Ear Infirmary at 8 sites in United States.
Trial summary
This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side in both eyes). Read more about this study
- Who is it for?
- Ages 7 years and older
- Conditions the study is for
- Homonymous Hemianopia
- What is being tested?
- Multi-Periscopic Prism (MPP) glasses and Fresnel Peripheral Prism (FPP) glasses
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 8 sitesUnited States
- Study dates
- 3 Apr 2023to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Homonymous hemianopia with or without macular sparing for at least 3 months
- Visual acuity of at least 20/50 in each eye, with correction if needed
- Refractive error in the -12D to +5D range
- Able to walk independently, using a cane or walker if needed
- Able to communicate in English sufficiently to understand the study procedures and how to use the prisms
Who cannot join
- Central visual field loss in the seeing hemifield of either eye (e.g. from macular degeneration, glaucoma, diabetic retinopathy or other maculopathies)
- Hemi-spatial neglect
- Significant cognitive impairment
- Dementia
- Any other physical or mental disabilities, or general health problems that could impair the ability to be independently mobile (i.e., walk ), participate in the VR walking simulator test or use the prism glasses
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
United States8 sites
UAB Center for Low Vision Rehabilitation, Callahan Eye Hospital
Birmingham, Alabama, 35233
Schepens Eye Research Institute
Boston, Massachusetts, 02114
New England College of Optometry
Boston, Massachusetts, 02215
Illinois College of Optometry
Chicago, Illinois, 60616
UCHealth Sue Anschutz-Rodgers Eye Center
Denver, Colorado, 80045
Visual Health and Surgical Center
Palm Springs, Florida, 33461
The Eye and Vision Center at MCPHS
Worcester, Massachusetts, 01608
UMass Chan Medical School
Worcester, Massachusetts, 01655
About this study
Official title: Randomized Controlled Multicenter Clinical Trial of Multi-Periscopic Prism Glasses for Homonymous Hemianopia
This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side in both eyes).
Read the detailed description
Patients with hemianopic field loss may be unaware of objects in their blind (non-seeing) hemi-field and often experience difficulties with hazards, such as walking into obstacles on the side of the field loss. Prism glasses that provide field of view expansion may be helpful in detecting hazards on the blind side. In this clinical trial, two types of high power prism glasses will be evaluated. A new design of prisms, Multi-Periscopic Prisms (MPP), will be compared to commercially-available permanent Fresnel peripheral prism (FPP) glasses. The extent to which the prismatic devices improve detection of hazards on the side of the field loss and are helpful when walking will be evaluated.
Participants will try each type of prism glasses at home for 4 weeks in counterbalanced order. Prism glasses will be fitted by Low Vision Practitioners at vision rehabilitation clinics. Participants will attend in-office study visits before and after wearing each type of prism glasses. At the in-office visits they will complete a test that involves detecting pedestrian hazards in a video simulating a walk through a busy shopping mall (virtual reality, VR, walking simulator test). In addition, they may be asked to complete questionnaires to record their experiences of using the prism glasses.
After wearing the second pair of prism glasses, participants will be asked to complete a questionnaire comparing the two types of prism glasses and to select their preferred type. A clinical decision will be made as to whether the participant should continue to use either the first or second pair of prism glasses (e.g. if a participant finds one pair of prism glasses helpful for obstacle avoidance when walking). For participants who continue with the prism glasses, telephone follow-up interviews will be conducted after about 6 and 12 months.
- Conditions
- Homonymous Hemianopia
- Being tested
- Multi-Periscopic Prism (MPP) glasses, Fresnel Peripheral Prism (FPP) glasses
- Medical subject headings
- Hemianopsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-Periscopic Prism (MPP) glassesDevice
Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
Fresnel Peripheral Prism (FPP) glassesDevice
Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
| Study group | Role | What they receive |
|---|---|---|
| MPP first, FPP second | Experimental | Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period. Receives: Device: Multi-Periscopic Prism (MPP) glasses; Device: Fresnel Peripheral Prism (FPP) glasses |
| FPP first, MPP second | Experimental | Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period. Receives: Device: Multi-Periscopic Prism (MPP) glasses; Device: Fresnel Peripheral Prism (FPP) glasses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 40 Degrees
Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 40 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.
Measured: Immediately after each 4-week intervention
Secondary outcomes (2)
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 20 Degrees
Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 20 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.
Measured: Immediately after each 4-week intervention
Device Preference
Number of participants selecting each device as a percentage of the total number of participants enrolled
Measured: Immediately after the second 4-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2021
- Study start3 Apr 2023
- Primary completion30 Apr 2025
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Homonymous HemianopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Sponsor type
- University, hospital or other
- Collaborators
- National Eye Institute (NEI)
- Responsible party
- Principal investigator, Eli Peli, Massachusetts Eye and Ear Infirmary
- Investigators
- Eli Peli, OD MSc, Principal investigator, Schepens Eye Research Institute of Massachusetts Eye and Ear
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04827147
- Sponsor's protocol ID
- 2021P003649
- Other IDs
- R01EY023385
- Status last verified
- Jul 2026
- First submitted
- 25 Mar 2021
- Last updated
- 19 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Bowers AR, Manda S, Shekar S, Hwang AD, Jung JH, Peli E. A randomized crossover clinical trial of multi-periscopic and Fresnel peripheral prism glasses for hemianopia. Optom Vis Sci. 2026 Jun;103(6):e70072. doi: 10.1002/ovs2.70072.
PubMed 42274646
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Multicenter Clinical Trial of Multi-Periscopic Prism Glasses for Homonymous Hemianopia
- ClinicalTrials.gov ID
- NCT04827147
- Acronym / sponsor ID
- 2021P003649
- Conditions
- Homonymous Hemianopia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Massachusetts Eye and Ear InfirmaryUniversity, hospital or other
- Collaborators
- National Eye Institute (NEI)
- Study start
- 3 Apr 2023 (actual)
- Primary completion
- 30 Apr 2025 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 1 Apr 2021 (actual)
- Results
- Posted 13 Mar 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side in both eyes).
Detailed description
Patients with hemianopic field loss may be unaware of objects in their blind (non-seeing) hemi-field and often experience difficulties with hazards, such as walking into obstacles on the side of the field loss. Prism glasses that provide field of view expansion may be helpful in detecting hazards on the blind side. In this clinical trial, two types of high power prism glasses will be evaluated. A new design of prisms, Multi-Periscopic Prisms (MPP), will be compared to commercially-available permanent Fresnel peripheral prism (FPP) glasses. The extent to which the prismatic devices improve detection of hazards on the side of the field loss and are helpful when walking will be evaluated.
Participants will try each type of prism glasses at home for 4 weeks in counterbalanced order. Prism glasses will be fitted by Low Vision Practitioners at vision rehabilitation clinics. Participants will attend in-office study visits before and after wearing each type of prism glasses. At the in-office visits they will complete a test that involves detecting pedestrian hazards in a video simulating a walk through a busy shopping mall (virtual reality, VR, walking simulator test). In addition, they may be asked to complete questionnaires to record their experiences of using the prism glasses.
After wearing the second pair of prism glasses, participants will be asked to complete a questionnaire comparing the two types of prism glasses and to select their preferred type. A clinical decision will be made as to whether the participant should continue to use either the first or second pair of prism glasses (e.g. if a participant finds one pair of prism glasses helpful for obstacle avoidance when walking). For participants who continue with the prism glasses, telephone follow-up interviews will be conducted after about 6 and 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MPP first, FPP second | Experimental | Device: Multi-Periscopic Prism (MPP) glasses, Device: Fresnel Peripheral Prism (FPP) glassesParticipants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period. |
| FPP first, MPP second | Experimental | Device: Multi-Periscopic Prism (MPP) glasses, Device: Fresnel Peripheral Prism (FPP) glassesParticipants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period. |
Who may qualify
- Ages
- 7 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Homonymous hemianopia with or without macular sparing for at least 3 months
- Visual acuity of at least 20/50 in each eye, with correction if needed
- Refractive error in the -12D to +5D range
- Able to walk independently, using a cane or walker if needed
- Able to communicate in English sufficiently to understand the study procedures and how to use the prisms
Key exclusion criteria (5 listed)
- Central visual field loss in the seeing hemifield of either eye (e.g. from macular degeneration, glaucoma, diabetic retinopathy or other maculopathies)
- Hemi-spatial neglect
- Significant cognitive impairment
- Dementia
- Any other physical or mental disabilities, or general health problems that could impair the ability to be independently mobile (i.e., walk ), participate in the VR walking simulator test or use the prism glasses
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-Periscopic Prism (MPP) glassesSpectacles with multi-periscopic prisms mounted as oblique peripheral prism segments | Device | FPP first, MPP second, MPP first, FPP second |
| Fresnel Peripheral Prism (FPP) glassesSpectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments | Device | FPP first, MPP second, MPP first, FPP second |
Primary outcome
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 40 Degrees
Time frame: Immediately after each 4-week intervention
Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 40 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.
2 secondary outcomes
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 20 Degrees
Time frame: Immediately after each 4-week intervention
Device Preference
Time frame: Immediately after the second 4-week intervention
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 42274646Bowers AR, Manda S, Shekar S, Hwang AD, Jung JH, Peli E. A randomized crossover clinical trial of multi-periscopic and Fresnel peripheral prism glasses for hemianopia. Optom Vis Sci. 2026 Jun;103(6):e70072. doi: 10.1002/ovs2.70072.
Related trials for Homonymous Hemianopia
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Ameliorating Stroke-induced Hemianopia Via Multisensory Training
Hemianopia, Homonymous, Cortical Blindness, Unspecified Side of Brain
Active, not recruiting
Statistical Learning as a Novel Intervention for Cortical Blindness
Stroke, Ischemic, Hemianopia, Homonymous
Not yet recruitingObservational study
Anatomical and Functional Predictions of Blindsight Capabilities in Patients With Lateral Hemianopsia
Homonymous Hemianopia, Stroke
Not yet recruiting
Effects of Optokinetic Stimulation Without a Reading Task in Patients With Hemianopic Alexia
Hemianopia Homonymous, Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eli Peli, OD MSc principal investigator
Schepens Eye Research Institute of Massachusetts Eye and Ear
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multi-Periscopic Prism (MPP) glasses and Fresnel Peripheral Prism (FPP) glasses in people with Homonymous Hemianopia, run by Massachusetts Eye and Ear Infirmary at 8 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 40 Degrees (time frame: Immediately after each 4-week intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04827147, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.